Scientists have identified a molecule produced by gut bacteria, imidazole propionate (ImP), as a potential key player in the development and progression of Alzheimer's disease. This compound appears to travel from the gut to the brain, where it may worsen the hallmarks of the disease, namely amyloid beta plaques and tau protein tangles.
The research, published in Nature Communications, suggests a compelling chain of events: certain gut bacteria metabolize the amino acid histidine, producing ImP. This molecule can then enter the bloodstream and potentially compromise the blood-brain barrier, allowing it to reach brain neurons. Once in the brain, ImP seems to accelerate the accumulation of amyloid beta and promote harmful modifications to tau proteins, both critical factors in Alzheimer's pathology.
To investigate this link, researchers analyzed ImP levels in the blood of nearly 1,200 cognitively healthy adults. Those with higher ImP concentrations performed worse on cognitive tests and showed elevated levels of biomarkers associated with Alzheimer's, such as pTau-217 and NfL, even before symptoms appeared. Furthermore, studies on mice genetically engineered to develop Alzheimer's-like conditions confirmed that ImP exacerbated disease markers, including amyloid beta plaque buildup and tau abnormalities.
It's important to note that the bacteria capable of producing ImP are common and can be found in healthy individuals. Their presence alone doesn't guarantee high ImP levels or the development of Alzheimer's. The concentration of ImP appears to be influenced by a complex interplay of factors including age, sex, genetics, diet, and the overall composition of the gut microbiome. Therefore, there isn't a single "Alzheimer's bacterium."
Looking ahead, the researchers propose that targeting ImP directly, rather than attempting to eradicate the bacteria, could be a promising therapeutic strategy. Similar to how statins manage cholesterol levels to reduce heart disease risk, a drug designed to lower ImP concentrations in the blood might offer a way to mitigate Alzheimer's risk by disrupting this gut-brain connection.
